Result of AGM

Verici Dx PLC

29 June 2023

 

Verici Dx plc

("Verici Dx" or the "Company")

Result of AGM and voting results

Verici Dx plc (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, announces that at the Annual General Meeting ("AGM") held earlier today, all resolutions were duly passed.

The voting results of the AGM were as follows:

	In Favour		Against		Withheld
Resolution	Votes	%	Votes	%	Votes
1	58,326,878	100	10	0	0
2	58,326,301	100	587	0	0
3	57,252,764	100	10	0	1,074,114
4	57,252,187	100	587	0	1,074,114

Enquiries:

Verici Dx	www.vericidx.com
Sara Barrington, CEO	Via Walbrook PR
Julian Baines, Chairman
Singer Capital Markets (Nominated Adviser & Broker)	Tel: [phone]
Aubrey Powell / Sam Butcher
Walbrook PR Limited	Tel: [phone] or [e-mail]
Paul McManus / Stephanie Cuthbert / Sam Allen	Mob: [phone] / 07502 558 258

About Verici Dx plc www.vericidx.com

Verici Dx is a developer of a complementary suite of leading-edge tests forming a kidney transplant platform for personalised patient and organ response risk to assist clinicians in medical management for improved patient outcomes. The underlying technology is based upon artificial intelligence assisted transcriptomic analysis to provide RNA signatures focused upon the immune response and other biological pathway signals critical for transplant prognosis of risk of injury, rejection and graft failure from pre-transplant to late stage.  The Company also has a mission to accelerate the pace of innovation by research using the fully characterised data from the underlying technology and collaboration with medical device, biopharmaceutical and data science partners.

The foundational research was driven by a deep understanding of cell-mediated immunity and is enabled by access to expertly curated collaborative studies in highly informative cohorts in kidney transplant.

Verici Dx's two lead products are Tutivia™, a post-transplant test focused upon acute cellular rejection, including sub-clinical rejection and Clarava™, a pre-transplant prognosis test for the risk of early acute rejection. These products seek to measure how a patient is likely to respond, and is responding, to a kidney transplant. These products are underpinned by extensive patented and published scientific research from the leading Mount Sinai Medical Center, for which the Company holds an exclusive worldwide licence.

 

END